Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Dimethyl Fumarate Delayed-Release Capsules

07 Oct 2020 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, the generic version of Tecfidera Delayed-Release Capsules, 120 mg and 240 mg, of Biogen, Inc. Sales data for the 12 month period ending August, the Tecfidera Delayed-Release Capsules, 120 mg and 240 mg market achieved annual sales of approximately $3.8 billion.

Glenmark’s current portfolio consists of 164 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1919.05 -46.70 (-2.38%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×